Analysts expect that Nektar Therapeutics (NASDAQ: NKTR – Get Rating) will post earnings per share of ($ 1.00) for the current quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($ 1.16) and the highest estimate coming in at ($ 0.67). Nektar Therapeutics posted earnings of ($ 0.69) per share during the same quarter last year, which would suggest a negative year over year growth rate of 44.9%. The firm is expected to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($ 2.31) per share for the current fiscal year, with EPS estimates ranging from ($ 2.66) to ($ 2.19). For the next financial year, analysts forecast that the firm will report earnings of ($ 1.16) per share, with EPS estimates ranging from ($ 2.28) to ($ 0.54). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ: NKTR – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($ 0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($ 0.72) by $ 0.23. The business had revenue of $ 24.82 million during the quarter, compared to analysts’ expectations of $ 24.89 million. Nektar Therapeutics had a negative return on equity of 65.64% and a negative net margin of 476.58%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted ($ 0.68) EPS.
A number of analysts recently weighed in on the company. Canaccord Genuity Group decreased their price target on Nektar Therapeutics from $ 25.00 to $ 6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. Oppenheimer downgraded Nektar Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 20th. JPMorgan Chase & Co. decreased their price target on Nektar Therapeutics from $ 24.00 to $ 17.00 in a research note on Tuesday, March 1st. StockNews.com upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Mizuho decreased their price target on Nektar Therapeutics from $ 8.00 to $ 6.00 and set a “neutral” rating on the stock in a research note on Monday, April 18th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $ 13.46.
In related news, insider Jonathan Zalevsky sold 21,673 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $ 3.95, for a total value of $ 85,608.35. Following the completion of the transaction, the insider now owns 276,399 shares of the company stock, valued at $ 1,091,776.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Howard W. Robin sold 36,529 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $ 3.95, for a total value of $ 144,289.55. Following the completion of the transaction, the chief executive officer now directly owns 620,941 shares of the company stock, valued at approximately $ 2,452,716.95. The disclosure for this sale can be found here. Over the last three months, insiders sold 84,627 shares of company stock valued at $ 334,277. Insiders own 2.91% of the company stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in NKTR. Credit Suisse AG raised its stake in Nektar Therapeutics by 7.2% during the third quarter. Credit Suisse AG now owns 186,370 shares of the biopharmaceutical company stock valued at $ 3,348,000 after buying an additional 12,502 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Nektar Therapeutics by 6.0% during the third quarter. The Manufacturers Life Insurance Company now owns 211,621 shares of the biopharmaceutical company stock valued at $ 3,801,000 after buying an additional 12,007 shares in the last quarter. Arizona State Retirement System raised its stake in Nektar Therapeutics by 1.8% during the third quarter. Arizona State Retirement System now owns 49,660 shares of the biopharmaceutical company stock valued at $ 892,000 after buying an additional 895 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in Nektar Therapeutics during the third quarter valued at approximately $ 278,000. Finally, Gs Investments Inc. acquired a new stake in shares of Nektar Therapeutics during the 3rd quarter worth approximately $ 359,000. Hedge funds and other institutional investors own 93.08% of the company stock.
Shares of NKTR stock opened at $ 3.63 on Friday. The business’s 50 day moving average is $ 4.54 and its two-hundred day moving average is $ 8.85. Nektar Therapeutics has a twelve month low of $ 3.30 and a twelve month high of $ 19.37. The company has a market capitalization of $ 676.17 million, a P / E ratio of -1.36 and a beta of 1.37.
Nektar Therapeutics Company Profile: (Get Rating)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1 / 2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)
For more information about research offers from Zacks Investment Research, visit Zacks.com:
Receive News & Ratings for Nektar Therapeutics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nektar Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.